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Abstract 
 A majority of cases of acute leukemia in infants, as well as a subset of secondary acute 
leukemia in adults is characterized by translocation of the MLL1 gene to generate an oncogenic 
MLL1 fusion protein.  The MLL1 fusion protein acts to abnormally recruit transcription-
promoting mechanisms to target gene loci, including HoxA9 and Meis1. Overexpression of 
MLL1 gene targets through these mechanisms results in transformation.  The MLL1 fusion 
protein has been found to cooperate with wild-type MLL1 to promote gene expression in 
leukemia.   Wild-type MLL1 is a histone methyltransferase with specificity for H3 at lysine 4 
(H3K4). Methyltransferase activity of MLL1 is stimulated through direct association with a 
conserved complex of proteins, WDR5, RbBP5 and ASH2L.  As H3K4 methylation is strongly 
correlated with transcription activation in MLL1 translocation leukemias, we sought to develop 
inhibitors for MLL1 methyltransferase activity based on our understanding of MLL1 complex 
regulation by its constituent components.  H3K4 methylation by the wild-type MLL1 complex is 
essential for expression of HoxA9 and Meis1 as well as transformation in leukemia. This activity 
is dependent on association between MLL1 and its direct interaction partner, WDR5.  To exploit 
the essential function of this interaction in leukemia, we have used rational design to develop 
cell-permeable, peptidomimetic inhibitors, MM-102 and MM-401, to the MLL1:WDR5 
interaction.  We demonstrate that both MM-102 and MM-401 specifically inhibit assembly of 
MLL1 with WDR5, RbBP5 and ASH2L and block methyltransferase activity of the MLL1 
complex.  We show that mouse and human leukemia cells, transformed with MLL1 fusion 
 viii 
proteins are specifically targeted by MM-401 and treatment with this compound results in 
differentiation or cell death.  We also show that inhibition of the MLL1:WDR5 interaction by 
MM-401 specifically impairs expression of HoxA9 and Meis1, as well as histone methylation at 
these loci.  These studies show that interaction between MLL1 and WDR5 is essential for 
expression of HoxA9 and Meis1 in leukemia. This also demonstrates that inhibition of the 
MLL1:WDR5 interaction has potential utility for treating leukemias with MLL1 
rearrangementand our compound MM-401, is a promising lead for future drug development.  
 
  
 
 
